Linezolid - Revision history

Danbot: Restore original dosing content alongside dynamic SMW tables

2026-03-20T02:38:34Z

Restore original dosing content alongside dynamic SMW tables

← Revisión anterior		Revisión del 02:38 20 mar 2026
Línea 6:		Línea 6:

	==Adult Dosing==		==Adult Dosing==
			*[[VRE]] infections:
			**600 mg PO/IV Q12H x 14-28 days
			*[[Pneumonia]], community-acquired:
			**600 mg PO/IV Q12H x 5 days
			*[[Pneumonia]], hospital-acquired or ventilator-associated:
			**600 mg PO/IV Q12H x 5 days
			*Uncomplicated [[skin infections]]:
			**400 mg PO Q12H x 10-14 days
			*Complicated [[skin infections]]:
			**600 mg PO/IV Q12H x 10-14 days
			*[[Endocarditis]]
			**600 mg PO/IV Q12H x 6 weeks


	===Indications by Disease===		===Indications by Disease===
	{{#ask: [[Has DrugName::Linezolid]] [[Has Population::Adult]]		{{#ask: [[Has DrugName::Linezolid]] [[Has Population::Adult]]
	\|?Treats disease=Disease		\|?Treats disease=Disease
	\|?Has Dose=Dose		\|?Has Dose=Dose
	\|?Has Context=Context		\|?Has Context=Context
	\|format=table		\|format=table
	\|limit=50		\|limit=50
	\|mainlabel=-		\|mainlabel=-
	\|headers=show		\|headers=show
	\|sort=Treats disease		\|sort=Treats disease
	}}		}}

	==Pediatric Dosing==		==Pediatric Dosing==
			*>12 years old: 600mg IV/PO q12h
			*<12 years: 10mg/kg IV/PO q8-12h


	===Indications by Disease===		===Indications by Disease===
	{{#ask: [[Has DrugName::Linezolid]] [[Has Population::Pediatric]]		{{#ask: [[Has DrugName::Linezolid]] [[Has Population::Pediatric]]
	\|?Treats disease=Disease		\|?Treats disease=Disease
	\|?Has Dose=Dose		\|?Has Dose=Dose
	\|?Has Context=Context		\|?Has Context=Context
	\|format=table		\|format=table
	\|limit=50		\|limit=50
	\|mainlabel=-		\|mainlabel=-
	\|headers=show		\|headers=show
	\|sort=Treats disease		\|sort=Treats disease
	}}		}}

Danbot: Replace manual dosing with dynamic SMW tables (Adult + Pediatric)

2026-03-20T01:52:27Z

Replace manual dosing with dynamic SMW tables (Adult + Pediatric)

← Revisión anterior		Revisión del 01:52 20 mar 2026
Línea 6:		Línea 6:

	==Adult Dosing==		==Adult Dosing==
	*[[~~VRE~~]] ~~infections:~~		===Indications by Disease===
	**600 mg PO/IV Q12H x 14-28 days		{{#ask: [[Has DrugName::Linezolid]] [[Has Population::Adult]]
	*[[~~Pneumonia~~]]~~, community-acquired:~~		\|?Treats disease=Disease
	**600 mg PO/IV Q12H x 5 days		\|?Has Dose=Dose
	*[[Pneumonia]], hospital-acquired or ventilator-associated:		\|?Has Context=Context
	**600 mg PO/IV Q12H x 5 days		\|format=table
	*Uncomplicated [[skin infections]]:		\|limit=50
	**400 mg PO Q12H x 10-~~14 days~~		\|mainlabel=-
	*Complicated [[skin infections]]:		\|headers=show
	**600 mg PO/IV Q12H x 10-14 days		\|sort=Treats disease
	*[[Endocarditis]]		}}
	**600 mg PO/IV Q12H x 6 weeks

	==Pediatric Dosing==		==Pediatric Dosing==
	*>12 years old: ~~600mg IV/PO q12h~~		===Indications by Disease===
	*<12 years: 10mg/kg IV/PO q8-~~12h~~		{{#ask: [[Has DrugName::Linezolid]] [[Has Population::Pediatric]]
			\|?Treats disease=Disease
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|format=table
			\|limit=50
			\|mainlabel=-
			\|headers=show
			\|sort=Treats disease
			}}

	==Special Populations==		==Special Populations==

Elcatracho: /* Serious */

2022-01-03T09:19:46Z

Serious

← Revisión anterior		Revisión del 09:19 3 ene 2022
Línea 38:		Línea 38:
	===Serious===		===Serious===
	*[[Serotonin syndrome]] can be caused with concomitant use with an SSRI or MAOI		*[[Serotonin syndrome]] can be caused with concomitant use with an SSRI or MAOI
	*Myelosuppression can occur after two ~~week~~ of use		*Myelosuppression can occur after two weeks of use
			*[[Thrombocytopenia]]<ref>Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007-1012. doi:10.1007/s15010-014-0674-5</ref>
	*Peripheral and optic neuropathy		*Peripheral and optic neuropathy
	*[[Lactic acidosis]]		*[[Lactic acidosis]]
	*Clostridium difficile diarrhea		*Clostridium difficile diarrhea
	*Liver injury		*Liver injury
	*Seizure		*Seizure

	===Common===		===Common===
	*GI upset		*GI upset

ClaireLewis: /* References */

2019-09-22T22:55:59Z

References

← Revisión anterior		Revisión del 22:55 22 sep 2019
Línea 184:		Línea 184:
	==References==		==References==
	<references/>		<references/>
			[[Category:ID]]
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Rossdonaldson1: Text replacement - "vancomycin " to "vancomycin "

2019-07-04T03:43:10Z

Text replacement - "vancomycin " to "vancomycin "

← Revisión anterior		Revisión del 03:43 4 jul 2019
Línea 3:		Línea 3:
	*Dosage Forms: PO/IV		*Dosage Forms: PO/IV
	*Common Trade Names: Zyvox		*Common Trade Names: Zyvox
	*Bacteriostatic, so prefer another agent in bacteremia, such as [[ceftaroline]] in vancomycin resistant MRSA		*Bacteriostatic, so prefer another agent in bacteremia, such as [[ceftaroline]] in [[vancomycin]] resistant MRSA

	==Adult Dosing==		==Adult Dosing==

Mholtz at 23:26, 30 August 2017

2017-08-30T23:26:38Z

← Revisión anterior		Revisión del 23:26 30 ago 2017
Línea 178:		Línea 178:
	===Key===		===Key===
	{{Template:Antibacterial Spectra Key}}		{{Template:Antibacterial Spectra Key}}

	==See Also==		==See Also==
	*[[Antibiotics (Main)]]		*[[Antibiotics (Main)]]

	==~~Source~~==		==References==

	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Mholtz: Text replacement - "* " to "*"

2017-07-24T01:13:04Z

Text replacement - "* " to "*"

← Revisión anterior		Revisión del 01:13 24 jul 2017
Línea 20:		Línea 20:

	==Pediatric Dosing==		==Pediatric Dosing==
	* >12 years old: 600mg IV/PO q12h		*>12 years old: 600mg IV/PO q12h
	*<12 years: 10mg/kg IV/PO q8-12h		*<12 years: 10mg/kg IV/PO q8-12h

Kxl328: /* General */

2017-06-25T20:20:40Z

General

← Revisión anterior		Revisión del 20:20 25 jun 2017
Línea 3:		Línea 3:
	*Dosage Forms: PO/IV		*Dosage Forms: PO/IV
	*Common Trade Names: Zyvox		*Common Trade Names: Zyvox
	*Bacteriostatic, so prefer another agent in bacteremia		*Bacteriostatic, so prefer another agent in bacteremia, such as [[ceftaroline]] in vancomycin resistant MRSA

	==Adult Dosing==		==Adult Dosing==

ClaireLewis at 16:45, 17 May 2017

2017-05-17T16:45:52Z

← Revisión anterior		Revisión del 16:45 17 may 2017
Línea 1:		Línea 1:
	==General==		==General==
	*Type: Oxazolidinone		*Type: Oxazolidinone [[antibiotic]]
	*Dosage Forms: PO/IV		*Dosage Forms: PO/IV
	*Common Trade Names: Zyvox		*Common Trade Names: Zyvox
Línea 20:		Línea 20:

	==Pediatric Dosing==		==Pediatric Dosing==
			* >12 years old: 600mg IV/PO q12h
			*<12 years: 10mg/kg IV/PO q8-12h

	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: ~~Caution advised during pregnancy~~		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: C
	*Lactation: ~~Safety Unknown~~		*Lactation: Infant risk cannot be ruled out
	*Renal Dosing		*Renal Dosing
	**~~Adult~~: ~~Caution advised. Give dose after hemodialysis.~~		**Renal impairment: no adjustment
	**~~Pediatric~~:		**Hemodialysis: give dose after HD
	*Hepatic ~~Dosing~~		Hepatic dosing: no adjustment for mild-moderate impairment (Child-Pugh Class A or B)
	**Adult: No adjustment for Child-Pugh Class A or B~~. Not defined for Child-Pugh Class C~~
	**Pediatric:

	==Contraindications==		==Contraindications==
	*Allergy to class/drug		*Allergy to class/drug
			*Use of MAOIs, concomitantly or within past 14 days

	==Adverse Reactions==		==Adverse Reactions==
Línea 40:		Línea 41:
	*Peripheral and optic neuropathy		*Peripheral and optic neuropathy
	*[[Lactic acidosis]]		*[[Lactic acidosis]]
			*Clostridium difficile diarrhea
			*Liver injury
			*Seizure
	===Common===		===Common===
	*GI upset		*GI upset
Línea 47:		Línea 50:

	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life: adults- 4.7-5.1h, pediatrics- 1.5-4.1
	*Metabolism:		*Metabolism:
	*Excretion:		*Excretion:
	*Mechanism of Action:
			==Mechanism of Action==


	==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==		==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==

Rossdonaldson1: /* Adult Dosing */

2017-05-17T05:16:25Z

Adult Dosing

← Revisión anterior		Revisión del 05:16 17 may 2017
Línea 6:		Línea 6:

	==Adult Dosing==		==Adult Dosing==
	*VRE infections:		*[[VRE]] infections:
	**600 mg PO/IV Q12H x 14-28 days		**600 mg PO/IV Q12H x 14-28 days
	*Pneumonia, community-acquired:		*[[Pneumonia]], community-acquired:
	**600 mg PO/IV Q12H x 5 days		**600 mg PO/IV Q12H x 5 days
	*Pneumonia, hospital-acquired or ventilator-associated:		*[[Pneumonia]], hospital-acquired or ventilator-associated:
	**600 mg PO/IV Q12H x 5 days		**600 mg PO/IV Q12H x 5 days
	*Uncomplicated skin infections:		*Uncomplicated [[skin infections]]:
	**400 mg PO Q12H x 10-14 days		**400 mg PO Q12H x 10-14 days
	*Complicated skin infections:		*Complicated [[skin infections]]:
	**600 mg PO/IV Q12H x 10-14 days		**600 mg PO/IV Q12H x 10-14 days
	*Endocarditis		*[[Endocarditis]]
	**600 mg PO/IV Q12H x 6 weeks		**600 mg PO/IV Q12H x 6 weeks